{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:10:21Z","timestamp":1790626221395,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"japan society for the promotion of science","doi-asserted-by":"publisher","award":["JP19H03527"],"award-info":[{"award-number":["JP19H03527"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"japan society for the promotion of science","doi-asserted-by":"publisher","award":["JP18K07255"],"award-info":[{"award-number":["JP18K07255"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"japan society for the promotion of science","doi-asserted-by":"publisher","award":["20K16462"],"award-info":[{"award-number":["20K16462"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant mesothelioma (MM) is a very aggressive tumor that develops from mesothelial cells, mainly due to asbestos exposure. MM is categorized into three major histological subtypes: epithelioid, sarcomatoid, and biphasic, with the biphasic subtype containing both epithelioid and sarcomatoid components. Patients with sarcomatoid mesothelioma usually show a poorer prognosis than those with epithelioid mesothelioma, but it is not clear how these morphological phenotypes are determined or changed during the oncogenic transformation of mesothelial cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We introduced the E6 and E7 genes of human papillomavirus type 16 and human telomerase reverse transcriptase gene in human peritoneal mesothelial cells and established three morphologically different types of immortalized mesothelial cell lines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>HOMC-B1 cells exhibited epithelioid morphology, HOMC-A4 cells were fibroblast-like, spindle-shaped, and HOMC-D4 cells had an intermediate morphology, indicating that these three cell lines closely mimicked the histological subtypes of MM. Gene expression profiling revealed increased expression of NOD-like receptor signaling-related genes in HOMC-A4 cells. Notably, the combination treatment of HOMC-D4 cells with TGF-\u03b2 and IL-1\u03b2 induced a morphological change from intermediate to sarcomatoid morphology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our established cell lines are useful for elucidating the fundamental mechanisms of mesothelial cell transformation and mesothelial-to-mesenchymal transition.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-021-02248-5","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T19:28:00Z","timestamp":1634585280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively"],"prefix":"10.1186","volume":"21","author":[{"given":"Tatsuhiro","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayao","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Akao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Kiyono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2428-3848","authenticated-orcid":false,"given":"Yoshitaka","family":"Sekido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"issue":"5","key":"2248_CR1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.fertnstert.2016.09.005","volume":"106","author":"SE Mutsaers","year":"2016","unstructured":"Mutsaers SE, Prele CM, Pengelly S, Herrick SE. Mesothelial cells and peritoneal homeostasis. Fertil Steril. 2016;106(5):1018\u201324.","journal-title":"Fertil Steril"},{"issue":"5","key":"2248_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa020809","volume":"348","author":"M Yanez-Mo","year":"2003","unstructured":"Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, Aguilera A, Sanchez-Tomero JA, Bajo MA, Alvarez V, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med. 2003;348(5):403\u201313.","journal-title":"N Engl J Med"},{"issue":"9","key":"2248_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/thoraxjnl-2013-204161","volume":"69","author":"A Reid","year":"2014","unstructured":"Reid A, de Klerk NH, Magnani C, Ferrante D, Berry G, Musk AW, Merler E. Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis. Thorax. 2014;69(9):843\u201350.","journal-title":"Thorax"},{"issue":"7","key":"2248_CR4","first-page":"1031","volume":"12","author":"B Liu","year":"2017","unstructured":"Liu B, van Gerwen M, Bonassi S, Taioli E. Epidemiology of environmental exposure and malignant mesothelioma. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12(7):1031\u201345.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"135","key":"2248_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1183\/09059180.00007014","volume":"24","author":"OD Roe","year":"2015","unstructured":"Roe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev Off J Eur Respir Soc. 2015;24(135):115\u201331.","journal-title":"Eur Respir Rev Off J Eur Respir Soc"},{"issue":"13","key":"2248_CR6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, et al. Treatment of malignant pleural mesothelioma: American society of clinical oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(13):1343\u201373.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"Suppl 1","key":"2248_CR7","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","volume":"73","author":"I Woolhouse","year":"2018","unstructured":"Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73(Suppl 1):i1\u201330.","journal-title":"Thorax"},{"issue":"12","key":"2248_CR8","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8(12):1548\u201365.","journal-title":"Cancer Discov"},{"issue":"4","key":"2248_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407\u201316.","journal-title":"Nat Genet"},{"issue":"4","key":"2248_CR10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/ijms19040988","volume":"19","author":"T Sato","year":"2018","unstructured":"Sato T, Sekido Y. NF2\/Merlin inactivation and potential therapeutic targets in mesothelioma. Int J Mol Sci. 2018;19(4):988.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2248_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/cancers10040090","volume":"10","author":"Y Sekido","year":"2018","unstructured":"Sekido Y. Targeting the hippo pathway is a new potential therapeutic modality for malignant mesothelioma. Cancers. 2018;10(4):90.","journal-title":"Cancers"},{"issue":"3","key":"2248_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1084\/jem.20111653","volume":"209","author":"M Fujii","year":"2012","unstructured":"Fujii M, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsudaira Y, Ito H, Murakami H, Kondo Y, Kondo E, et al. TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 2012;209(3):479\u201394.","journal-title":"J Exp Med"},{"issue":"4","key":"2248_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/path.4377","volume":"233","author":"L Jiang","year":"2014","unstructured":"Jiang L, Yamashita Y, Chew SH, Akatsuka S, Ukai S, Wang S, Nagai H, Okazaki Y, Takahashi T, Toyokuni S. Connective tissue growth factor and beta-catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma. J Pathol. 2014;233(4):402\u201314.","journal-title":"J Pathol"},{"issue":"6","key":"2248_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/1878-0261.12651","volume":"14","author":"L Quetel","year":"2020","unstructured":"Quetel L, Meiller C, Assie JB, Blum Y, Imbeaud S, Montagne F, Tranchant R, de Wolf J, Caruso S, Copin MC, et al. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol. 2020;14(6):1207\u201323.","journal-title":"Mol Oncol"},{"issue":"6","key":"2248_CR15","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/S0002-9440(10)63583-3","volume":"163","author":"S Kyo","year":"2003","unstructured":"Kyo S, Nakamura M, Kiyono T, Maida Y, Kanaya T, Tanaka M, Yatabe N, Inoue M. Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol. 2003;163(6):2259\u201369.","journal-title":"Am J Pathol"},{"issue":"11","key":"2248_CR16","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/carcin\/bgw084","volume":"37","author":"T Kakiuchi","year":"2016","unstructured":"Kakiuchi T, Takahara T, Kasugai Y, Arita K, Yoshida N, Karube K, Suguro M, Matsuo K, Nakanishi H, Kiyono T, et al. Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation. Carcinogenesis. 2016;37(11):1098\u2013109.","journal-title":"Carcinogenesis"},{"issue":"43","key":"2248_CR17","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2248_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0165-4608(02)00536-8","volume":"137","author":"Y Sekido","year":"2002","unstructured":"Sekido Y, Sato M, Usami N, Shigemitsu K, Mori S, Maeda O, Yokoi T, Hasegawa Y, Yoshioka H, Shimokata K. Establishment of a large cell lung cancer cell line (Y-ML-1B) producing granulocyte colony-stimulating factor. Cancer Genet Cytogenet. 2002;137(1):33\u201342.","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"2248_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cell.2009.03.023","volume":"137","author":"JM Gerdes","year":"2009","unstructured":"Gerdes JM, Davis EE, Katsanis N. The vertebrate primary cilium in development, homeostasis, and disease. Cell. 2009;137(1):32\u201345.","journal-title":"Cell"},{"issue":"3","key":"2248_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x","volume":"98","author":"T Taniguchi","year":"2007","unstructured":"Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, Ueda Y, Mitsudomi T, Horio Y, Hida T, et al. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci. 2007;98(3):438\u201346.","journal-title":"Cancer Sci"},{"issue":"7","key":"2248_CR21","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","volume":"30","author":"K Kawaguchi","year":"2009","unstructured":"Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 2009;30(7):1097\u2013105.","journal-title":"Carcinogenesis"},{"issue":"11","key":"2248_CR22","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41388-018-0417-7","volume":"38","author":"A Matsushita","year":"2019","unstructured":"Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, Aoki M, Hasegawa Y, Sekido Y. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation. Oncogene. 2019;38(11):1966\u201378.","journal-title":"Oncogene"},{"issue":"1","key":"2248_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","volume":"196","author":"RR Meyerhoff","year":"2015","unstructured":"Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D\u2019Amico TA, Harpole DH, Berry MF. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J Surg Res. 2015;196(1):23\u201332.","journal-title":"J Surg Res"},{"issue":"11","key":"2248_CR24","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.3390\/ijms21114158","volume":"21","author":"RB Wilson","year":"2020","unstructured":"Wilson RB, Archid R, Reymond MA. Reprogramming of mesothelial\u2013mesenchymal transition in chronic peritoneal diseases by estrogen receptor modulation and TGF-beta1 inhibition. Int J Mol Sci. 2020;21(11):4158.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2248_CR25","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/cancers7040872","volume":"7","author":"A Rynne-Vidal","year":"2015","unstructured":"Rynne-Vidal A, Jimenez-Heffernan JA, Fernandez-Chacon C, Lopez-Cabrera M, Sandoval P. The mesothelial origin of carcinoma associated-fibroblasts in peritoneal metastasis. Cancers. 2015;7(4):1994\u20132011.","journal-title":"Cancers"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02248-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-021-02248-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02248-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T19:43:57Z","timestamp":1634586237000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-021-02248-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2248"],"URL":"https:\/\/doi.org\/10.1186\/s12935-021-02248-5","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"12 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The omental tissue was obtained from a patient according to protocols approved by the Institutional Review Board, and written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"546"}}